Vol 31, No 1 (2024)
Original Article
Published online: 2023-07-28

open access

Page views 747
Article views/downloads 390
Get Citation

Connect on Social Media

Connect on Social Media

Long-term bio-functional performance of a novel, self-positioning balloon expandable transcatheter biological aortic valve system in the ovine aortic banding model

Piotr P. Buszman12, Mateusz Kachel21, Krzysztof P. Milewski23, Magdalena Michalak2, Wojciech Domaradzki2, Maciej Pruski Jr2, Michał Sobota4, Carlos Fernandez2, Karolina Łukasik2, Jerzy Nożyński5, Piotr Hirnle6, Paweł Kaźmierczak2, Andrzej Bochenek23, Paweł E. Buszman27
Pubmed: 37519054
Cardiol J 2024;31(1):124-132.

Abstract

Background: The aim of the study was to evaluate bio-functionality of a novel, proprietary balloon-expandable biological transcatheter aortic valve implantation (TAVI) system (InFlow, CardValve Consortium, Poland) in an ovine model of aortic banding.

Methods: Surgical ascending aorta banding was created in 21 sheep. Two weeks later, 18 biological valves were implanted within the model using 15–16 F InFlow TAVI systems and carotid cut-down approach. Follow-up transthoracic echocardiography was performed at 30, 90, and 180-day. At designated time, animals were euthanized and valves harvested for analysis.

Results: All sheep survived the banding procedure. There were 4 (22%) procedure related deaths within a 7-day period. During the observation an additional 2 sheep died. In one, the valve dislocated after the procedure — the animal was excluded. Two animals completed 30-day follow up, five 90-day follow-up and four terminal follow-up of 180 days. Valves examined via transesophageal echocardiography showed proper hemodynamic parameters without evidence of structural valve deterioration. The maximum and average flow gradients at 180 days were 31.4 (23.3–37.7) and 17.5 (13.1–20.2) mmHg, respectively. There was one case of moderate insufficiency and no case of perivalvular leaks. By histopathology, there were no inflammation, thrombosis, nor calcifications in any tested valves at long-term follow-up. Neointimal coverage of stent struts increased with time from basal part in “early” groups to nearly 3/4 of stent length in the 180-day group. The pannus tissue showed maturation that increased with time with no stenotic “collar” visible in orthotopically implanted valves.

Conclusions: The study showed good hemodynamic performance, durability and biocompatibility of the novel biological THV.

Article available in PDF format

View PDF Download PDF file

References

  1. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002; 106(24): 3006–3008.
  2. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022; 43(7): 561–632.
  3. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021; 143(5): e35–e71.
  4. Siontis GCM, Praz F, Pilgrim T, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. Eur Heart J. 2016; 37(47): 3503–3512.
  5. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016; 374(17): 1609–1620.
  6. Reardon MJ, Mieghem NV, Popma J, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017; 376(14): 1321–1331.
  7. Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol. 2021; 77(9): 1149–1161.
  8. Forrest JK, Deeb GM, Yakubov SJ, et al. 2-Year outcomes after transcatheter versus surgical aortic valve replacement in low-risk patients. J Am Coll Cardiol. 2022; 79(9): 882–896.
  9. Carroll J, Mack M, Vemulapalli S, et al. STS-ACC TVT Registry of transcatheter aortic valve replacement. J Am Coll Cardiol. 2020; 76(21): 2492–2516.
  10. Durko AP, Osnabrugge RL, Van Mieghem NM, et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. Eur Heart J. 2018; 39(28): 2635–2642.
  11. De Biase C, Mastrokostopoulos A, Philippart R, et al. What are the remaining limitations of TAVI? J Cardiovasc Surg (Torino). 2018; 59(3): 373–380.
  12. National Research Council. 2011. Guide for the Care and Use of Laboratory Animals: Eighth Edition. Washington, DC: The National Academies Press. https://doi.org/10.17226/12910.
  13. Buszman PP, Kachel M, Ceballos CF, et al. 6-Month evaluation of a transcatheter aortic valve (Myval) in a novel ovine, supra-aortic banding model. JACC Basic Transl Sci. 2022; 7(5): 486–495.
  14. U.S. Food and Drug Administration Summary of Safety and Effectiveness Data, Replacement Heart Valve, Edwards Sapien Transcatheter Heart Valve. U.S. Food and Drug Administration; 2012. Application P110021. https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110021b.pdf (Accessed May 25, 2022).
  15. Eltchaninoff H, Nusimovici-Avadis D, Babaliaros V, et al. Five month study of percutaneous heart valves in the systemic circulation of sheep using a novel model of aortic insufficiency. EuroIntervention. 2006; 1(4): 438–444.
  16. Carney JP, Schappa Faustich J, Lahti MT, et al. New Model for the Assessment of Transcatheter Aortic Valve Replacement Devices in Sheep. J Invest Surg. 2022; 35(2): 371–377.
  17. Scherman J, Ofoegbu C, Myburgh A, et al. Preclinical evaluation of a transcatheter aortic valve replacement system for patients with rheumatic heart disease. EuroIntervention. 2019; 15(11): e975–e982.